CANCER

Recommendations

Info

Bloodwise 36 STRATEGIC REPORT TYPE OF RESEARCH INVESTMENT IN FY15: COMPARISON WITH FY14 AMOUNT FY15 AMOUNT FY14 32% (£10.2m) 44% (£14.3m) 16% (£3.6m) 13% (£3.1m) 47% (£11m) 11% (£3.4m) 13% (£4.4m) 24% (£5.5m) Programmes Projects Career development TAP, clinical trails and related research Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089 Registered charity 216032 (England & Wales) SC037529 (Scotland)
Bloodwise 37 STRATEGIC REPORT RESEARCH INVESTMENT IN FY15: BY BLOOD <strong>CANCER</strong> TYPE Our understanding of the biology of blood cancers means that we understand the control mechanisms that must be disrupted for cancer to take hold. This means that what we learn for one blood cancer can be relevant to many others – and many other cancers too. So in some respects it’s hard to divide our research portfolio by blood cancer type. However we know that many people like to check for investment in their particular blood cancer, so this chart gives a rough guide to the primary focus areas of our new commitments made this year. COMMITMENTS FY15 COMMITMENTS FY14 4%4% Leukaemia 12% 27% 12% Multi (including TAP) Lymphoma 11% 8% 5% 51% 20% MDS & MPN Children’s blood cancers 37% 9% Myeloma PATIENT EXPERIENCE We’ve increased our expenditure on patient activities this year by 84% to £1.5 million (FY14: £0.8 million). This has included the establishment of a patient services team to inform and engage patients; the revision and renewal of a number of our patient information booklets; and our patient need research. As we establish our patient services directorate, do more to improve the lives of patients and respond to our patient need research findings over the coming years this investment will continue to grow. Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089 Registered charity 216032 (England & Wales) SC037529 (Scotland)
Page 1 and 2: Leukaemia & Lymphoma Research 1 Not
Page 3 and 4: Bloodwise 3 Report of the Trustees
Page 7 and 8: Bloodwise 7 STRATEGIC REPORT STRATE
Page 9 and 10: Bloodwise 9 STRATEGIC REPORT GOAL 1
Page 11 and 12: Bloodwise 11 STRATEGIC REPORT HIDIN
Page 13 and 14: Bloodwise 13 STRATEGIC REPORT FUELL
Page 15 and 16: Bloodwise 15 STRATEGIC REPORT Cradd
Page 17 and 18: Bloodwise 17 STRATEGIC REPORT RESEA
Page 19 and 20: Bloodwise 19 STRATEGIC REPORT 2. PR
Page 21 and 22: Bloodwise 21 STRATEGIC REPORT A VOI
Page 23 and 24: Bloodwise 23 STRATEGIC REPORT and n
Page 25 and 26: Bloodwise 25 STRATEGIC REPORT GOAL
Page 27 and 28: Bloodwise 27 STRATEGIC REPORT GOAL
Page 29 and 30: Bloodwise 29 STRATEGIC REPORT OUR S
Page 31 and 32: Bloodwise 31 STRATEGIC REPORT THE Y
Page 33 and 34: Bloodwise 33 STRATEGIC REPORT REGIO
Page 35: Bloodwise 35 STRATEGIC REPORT RESEA
Page 39 and 40: Bloodwise 39 STRATEGIC REPORT INVES
Page 41 and 42: Bloodwise 41 STRATEGIC REPORT In Fe
Page 43 and 44: Bloodwise 43 HOW WE HOW WORK WE Our
Page 45 and 46: Bloodwise 45 HOW WE WORK OUR APPLIC
Page 47 and 48: Bloodwise 47 STATEMENT OF TRUSTEE R
Page 49 and 50: Bloodwise 49 INDEPENDENT AUDITOR’
Page 51 and 52: Bloodwise 51 Group statement of fin
Page 53 and 54: Bloodwise 53 Group cash flow statem
Page 55 and 56: Bloodwise 55 Accounting policies fo
Page 57 and 58: Bloodwise 57 Notes to the Accounts

CANCER

Create successful ePaper yourself

Delete template?

Save as template?